Navigation Links
Sosei Announces Deal With UK Biotech Company
Date:10/14/2009

TOKYO, Japan, October 14 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), a biopharmaceutical company, today announces the assignment of the drug discovery programme, SD281 and its analogues, to Biocopea Limited, a UK biotechnology company and subsidiary of PepTcell Limited. These compounds, based on a metabolite of a well-known drug, were shown by Sosei to have pronounced anti-inflammatory properties. Sosei had positioned the compounds for intervention in inflammatory diseases such as Inflammatory Bowel Disease (IBD). Biocopea intends to develop the portfolio of compounds further using its specialized chemical design, specific disease models and immunology expertise.

The deal means that a promising class of new chemical entities with a long remaining patent life can be taken forward by a partner committed to the development of new therapies for a variety of immune diseases. Under the terms of the assignment, Sosei will receive payments when the compounds are commercialized by Biocopea or its partners.

Notes for Editors:

About Sosei

Sosei Group Corporation is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit http://www.sosei.com

About Biocopea

Biocopea is focussed upon the identification and exploitation of novel biology from existing drug templates. It is 75% owned by PepTcell Limited, a biotechnology company with the aim of converting theoretical concepts into novel analytical tools and clinical products, in the field of immunology.

For further information about Biocopea, please visit http://www.bicopea.com

SOURCE Sosei Group Corporation


'/>"/>
SOURCE Sosei Group Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sosei Announces Filing of NDA for SOH-075 (NorLevo(R)) in Japan
2. Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria
3. Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
4. Sosei Announces Outcome of Strategy Review
5. Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
6. Systagenix Announces Formation of New Global Medical Advisory Board to Support Future Clinical Advances in Wound Care
7. Health Robotics Announces First Five i.v.STATION(TM) Robot Shipments and Receipt of 3L/3T Innovation Award
8. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
10. Nanogea Announces New Scientific Advisory Board Members
11. CardioDx Announces Appointment of Dr. Louis G. Lange as Chairman of the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 2016 According to the ... Products (Consumable, Instruments, Automated Cell Expansion System), Cells ... Cell Research, Cancer, and Cell-Based Research), End-users (Biopharmaceutical ... Global Revenue, Trends, Growth, Share, Size and Forecast ... global cell expansion market is expected to reach ...
(Date:12/5/2016)... WOODCLIFF LAKE, N.J. , Dec. 5, 2016 ... its Phase 3 open-label two-year study of rufinamide, ... of the American Epilepsy Society (AES) held from ... . Analysis of final two-year safety, tolerability and ... therapy with rufinamide experienced similar safety and tolerability ...
(Date:12/4/2016)... (PRWEB) , ... December 03, 2016 , ... ... ground-breaking microbiome studies. A microbiome impact grant award has been made to Dr. ... of heavy smoking and drinking on the oral microbiome. Grant proposals have been ...
(Date:12/2/2016)... 2016 More than $4.3 million was raised last ... DHMD ). The gala was held at the American Museum ... and honored Alan Alda and ... and medicine and the public understanding of science. Since the ... event has raised $40 million for the Laboratory,s research and ...
Breaking Biology Technology:
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
(Date:6/22/2016)... , June 22, 2016  The American College of Medical ... Show Executive Magazine as one of the fastest-growing trade ... 25-27 at the Bellagio in Las Vegas ... highest percentage of growth in each of the following categories: ... companies and number of attendees. The 2015 ACMG Annual Meeting ...
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
Breaking Biology News(10 mins):